The legal potion

IIPM BUSINESS & ECONOMY
So, Kindler is the new guy on the watch… from courtrooms to boardrooms, from analysts & investors to the press, Pfizer has a new face. But is this drive going to be smooth, at a juncture when Pfizer seems all but set to nail its coffin? Currently, Pfizer is going through a stagnated growth period and it has become problematic for the company to improve its financials (see table). And that’s not all, the bleak situation has worsened – its key drugs like Zoloft and Lipitor are facing patent expiry. The company was also asked by the FDA to remove its popular arthritis drug Bextra from the market, which affected Celebrex sales as well.

The legal beagle would surely need all the tricks up his sleeve to protect Pfizer from charged up competitors in the courtrooms. Kindler would also do well to use some of McKinnell’s acquisition skills that helped Pfizer achieve dizzying heights. And above all, Kindler has to accomplish what even McKinnell couldn’t; rescuing an ailing Pfizer from its stupor by bringing in new block buster drugs to the market faster than they move out of the patent protection umbrella. Surely, both McKinnell and Kindler have a lot to brood over in the coming time...

For Complete IIPM Articles, Click here

Source :- IIPM Editorial, 2006, Editor - Prof. Arindam Chaudhuri

For more IIPM info, Visit below....
http://www-management-courses.ebloggy.com/
http://iipm-institute.21publish.com/
http://iipm-institute.21publish.com/vidhhyalaya
http://iipm-b-school.blog.ca/
http://sonuright.bravehost.com
http://www.freewebs.com/iipm-institute/index.htm
http://www.journalscape.com/iipm/
http://iipminstitute.blogonfly.com
http://sonu-site.supersized.org
http://surendersingh.bloggoing.com/
http://sonusingh.alfablog.com/
http://www.journalhome.com/iipmblog